CIHR 5-Year Evaluation Schedule (2009-2010 – 2013-2014)

The following schedules outline the timing of program evaluations at CIHR for Fiscal Year 2008/09 through to 2012/13. The proposed evaluations generally require six months for planning and one full year for the conduct of the study, at the end of which an evaluation report is expected. The programs are listed by Program Activity Architectures (PAA) number followed by the program title. The timelines are indicated in brackets (Q1 = first quarter etc). These are estimates based on the current resources available to the Evaluation Unit and the governance structures in place at CIHR. Evaluations not led by CIHR's Evaluation Branch are identified with an asterisk *.

2009-2010

1. Planning an evaluation

External Review of CIHR (Q1, Q2, Q3)
1.2.1 Strategic Priority Operating Grant Programs (Q3, Q4)
1.2.2 Large Strategic Initiatives Program (Q2, Q3)
2.1.1 Salary Support Programs (Q2, Q3)
2.1.5 Strategic Salary Support Programs (Q2, Q3)
2.2.1 Research Resources, Collaboration (Q1, Q2)
3.2.1 Commercialization Funding Programs (Q1, Q2)

2. Ongoing Evaluation

External Review of CIHR (Q4)
1.1.1 Open Operating Grant Program (Q1, Q2, Q3)
1.1.2 Randomized Controlled Trials Program (Q1, Q2, Q3, Q4)
1.1.3 Team Grant Program (Q1, Q2, Q3, Q4)
1.2.1 Strategic Priority Operating Grant Programs (Q3, Q4)
1.2.2 Large Strategic Initiatives Program (Q4)
1.2.4 Pandemic Preparedness Research Initiative * (Q1, Q2)
2.1.1 Salary Support Programs (Q4)
2.1.3 Canada Research Chairs Grant Program * (Q1, Q2, Q3, Q4)
2.1.5 Strategic Salary Support Programs (Q4)
2.2.1 Research Resources, Collaboration (Q1, Q2, Q3, Q4)
3.2.1 Commercialization Funding Programs (Q3, Q4)

3. Evaluation Report

1.1.1 Open Operating Grant Program (Q4)
1.2.4 Pandemic Preparedness Research Initiative * (Q3)

2010-2011

1. Planning an evaluation

1.1.1 Open Operating Grant Program (Q1)
1.2.3 HIV/AIDS Research Initiative * (Q2, Q3)
1.2.5 Expensive Drugs for Rare Diseases Research Initiative * (Q1, Q2)
2.3.2 Partnership Programs (Q1, Q2)
3.1.1 Knowledge Translation Program (Q3, Q4)

2. Ongoing Evaluation

External Review of CIHR (Q1, Q2, Q3, Q4)
1.1.1 Open Operating Grant Program (Q2, Q3, Q4)
1.2.1 Strategic Priority Operating Grant Programs (Q1, Q2, Q3, Q4)
1.2.2 Large Strategic Initiatives Program (Q1, Q2, Q3, Q4)
1.2.3 HIV/AIDS Research Initiative * (Q4)
1.2.5 Expensive Drugs for Rare Diseases Research Initiative * (Q3, Q4)
2.1.1 Salary Support Programs (Q1, Q2, Q3)
2.1.3 Canada Research Chairs Grant Program * (Q1)
2.1.5 Strategic Salary Support Programs (Q1, Q2 Q3)
2.3.2 Partnership Programs (Q3, Q4)
3.2.1 Commercialization Funding Programs (Q1, Q2)

3. Evaluation Report

1.1.2 Randomized Controlled Trials Program (Q1)
1.1.3 Team Grant Program (Q1)
2.1.1 Salary Support Programs (Q4)
2.1.3 Canada Research Chairs Grant Program * (Q2)
2.1.5 Strategic Salary Support Programs (Q4)
2.2.1 Research Resources, Collaboration (Q1)
3.2.1 Commercialization Funding Programs (Q3)

2011-2012

1. Planning an evaluation

1.1.1 Open Operating Grant Program (Q1, Q2)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative * (Q1, Q2)
2.1.2 Training Support Programs (Q2, Q3)
2.1.4 Canada Graduate Scholarships Program (Q2)
2.1.6 Strategic Training Support Programs (Q2, Q3)
2.3.1 Institute Support Grants (Q4)
3.1.2 Networks of Centers of Excellence Program * (Q2, Q3)

2. Ongoing Evaluation

1.1.1 Open Operating Grant Program (Q3, Q4)
1.2.3 HIV/AIDS Research Initiative * (Q1, Q2, Q3)
1.2.5 Expensive Drugs for Rare Diseases Research Initiative * (Q1, Q2)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative * (Q3, Q4)
2.1.2 Training Support Programs (Q4)
2.1.4 Canada Graduate Scholarships Program (Q3, Q4)
2.1.6 Strategic Training Support Programs (Q4)
2.3.2 Partnership Programs (Q1, Q2)
3.1.1 Knowledge Translation Program (Q1, Q2, Q3, Q4)
3.1.2 Networks of Centers of Excellence Program * (Q4)

3. Evaluation Report

1.1.1 Open Operating Grant Program (Q1)
1.2.1 Strategic Priority Operating Grant Programs (Q1)
1.2.2 Large Strategic Initiatives Program (Q1)
1.2.3 HIV/AIDS Research Initiative * (Q4)
1.2.5 Expensive Drugs for Rare Diseases Research Initiative * (Q3)
2.3.2 Partnership Programs (Q3)

2012-2013

1. Planning an evaluation

1.1.1 Open Operating Grant Program (Q3)
2.3.1 Institute Support Grants (Q1)
2.4    Ethical, Legal, Social Issues (Q2, Q3)

2. Ongoing Evaluation

1.1.1 Open Operating Grant Program (Q1, Q4)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative * (Q1, Q2)
2.1.2 Training Support Programs (Q1, Q2, Q3, Q4)
2.1.4 Canada Graduate Scholarships Program (Q1, Q2)
2.1.6 Strategic Training Support Programs (Q1, Q2, Q3, Q4)
2.3.1 Institute Support Grants (Q2, Q3, Q4)
2.4    Ethical, Legal, Social Issues (Q4)
3.1.2 Networks of Centers of Excellence Program * (Q1, Q2, Q3)

3. Evaluation Report

1.1.1 Open Operating Grant Program (Q2)
1.2.6 National Anti-Drug Strategy Treatment Research Initiative * (Q3)
2.1.4 Canada Graduate Scholarships Program (Q3)
3.1.1 Knowledge Translation Program (Q1)
3.1.2 Networks of Centers of Excellence Program * (Q4)

2013-2014

1. Planning an evaluation

2. Ongoing Evaluation

1.1.1 Open Operating Grant Program (Q1, Q2, Q3)
2.3.1 Institute Support Grants (Q1)
2.4    Ethical, Legal, Social Issues (Q1, Q2)

3. Evaluation Report

1.1.1 Open Operating Grant Program (Q4)
2.1.2 Training Support Programs (Q1)
2.1.6 Strategic Training Support Programs (Q1)
2.3.1 Institute Support Grants (Q2)
2.4    Ethical, Legal, Social Issues (Q3)